Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.030 -2.620 (-34.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden. 
Via Benzinga
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
From Alvotech
Via GlobeNewswire
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Alvotech's Earnings Outlook
 
Via Benzinga
ALVO Stock Earnings: Alvotech Misses Revenue for Q2 2024
ALVO stock results show that Alvotech missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
From Alvotech
Via GlobeNewswire
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Teva Pharmaceutical Industries Ltd; Alvotech
Via GlobeNewswire
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
From Alvotech
Via GlobeNewswire
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for the First Nine Months of 2024
From Alvotech
Via GlobeNewswire
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Alvotech
Via GlobeNewswire
Vipshop, Hesai Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.